Friday, February 26, 2010

Zecotek Photonics Touts Green Fiber Laser and Files for Patents for 3D Displays

Zecotek Photonics Inc.,  a developer of leading-edge photonics technologies for medical, industrial and scientific markets, on February 18th  reported the company’s proprietary green fiber laser technology platform was  highlighted during a key note address at the Lasers and Photonics Marketplace Seminar which was held in parallel with the 2010 Photonics West Conference in San Francisco.  Dr. William Telford, a staff scientist and faculty head of the National Cancer Institute, featured the Green Fiber Laser in his talk which discussed specifications of various lasers used in flow cytometry.

“Although the number of fluorescent proteins available for research has exploded in number in the past five years, most flow cytometers cannot take advantage of the opportunity to research these proteins due to laser limitations,” said Dr. Telford.  “Modern laser technology, such as Zecotek’s Green Fiber Laser, is eliminating this limitation.  The broad range of operating wavelengths enables accurate matching to fluorescent targets, thus optimizing analysis.”

Dr. Telford described Zecotek's 550-nm green fiber laser and explained that this laser's technology platform, utilizing a novel laser cavity design, can enable various lasers with wavelengths from 515 to 560 nm. His presentation also indicated that Zecotek's 550-nm green fiber laser was as powerful as comparable 532-nm and 561-nm sources, but is more compatible with standard fluorescent markers.

A more detailed description of Zecotek’s Green Fiber Laser applications in flow cytometry will be available in a jointly authored paper by the National Institute of Health and Zecotek in a forthcoming edition of the journal Cytometry Part A titled “Green Fiber Lasers: an alternative to traditional DPSS green lasers for flow cytometry” by Dr. William G. Telford, et al.

The world market for flow cytometry systems is about $1.5 billion (about 68% of which is for instruments and 32% for chemical reagents), The market is estimated to more than double by 2015 (Source: 2008 Flow Cytometry Report, Biocompare Surveys and Reports). Approximately 1,500 to 2,000 flow cytometry units are delivered annually, many of which use several lasers to illuminate cells.

Zecotek's visible wavelength fiber lasers have been specifically developed as higher performance, lower cost replacements for argon-ion and solid-state laser wavelengths in applications including: bio-instrumentation (DNA Sequencing, Flow Cytometry, Scanning Laser Microscopy), medicine (Ophthalmology, Dermatology, Urology), printing and imaging, inspection and measurement, laser writing and lithography, and fundamental research
(Spectroscopy, Fluorescence Analysis). 

Zecotek has filed for patent protection for its Real-Time 3D2D Display system in India, where Zecotek has identified significant opportunities. This follows applications submitted in the US, to the Patent Cooperation Treaty (PCT), and to other regional and national jurisdictions. Patents have been granted in Australia and are pending in the United States, Japan, China, Russia, Korea and major countries in Europe. Protection of intellectual property is crucial as Zecotek is currently demonstrating its 3D display system in Europe, Asia and North America and looks to conclude a manufacturing or licensing partnership with a major OEM.

"Our 3D prototype meets and exceeds the performance specifications required for immediate applications in medical imaging, security, geo-survey, advertising and entertainment as we look to secure a manufacturing agreement in the near future," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "In order to maintain our leadership position in this competitive technology space, the strengthening of the patent protection of our unique 3D technological innovation is a priority, and it is being achieved through additional innovative claims and multiple stage patents in all countries where significant demand for our 3D products is expected."

Zecotek's Real-Time 3D2D Display System is based on the auto-stereoscopic principle, but with substantial innovative and patented improvements and represents a new and unique generation of 3D displays. While auto-stereoscopic 3D is true 3D, stereoscopic 3D requires the viewer to wear special glasses. Zecotek's true, multi-view 3D2D Display system requires no glasses and has an effective viewing angle of 40 degrees with 90 concurrent perspectives. The system is also scalable and offers both small 3D display screens for use in the transportation, personal computing and gaming industries, and large 3D display screens designed to meet the expected demand for industrial, advertisement, medical and home entertainment markets.

Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry.  Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. 

Zecotek Photonics Inc.
Suite 408-6190 Agronomy Road
University of British Columbia
Vancouver, BC, V6T 1Z3
Tel: +1 604 827 5212
Fax: +1 604 827 5214

No comments:

Post a Comment